Alex Herrera

2 months ago | ascopost.com | Syed Abutalib |Alex Herrera |Álex Herrera

“It isn’t the mountains ahead to climb that wear you out; it’s the pebble in your shoe.”—Muhammad AliLong-term survival in early-stage classic Hodgkin lymphoma (cHL) was first made possible by the introduction of the mantle and inverted Y fields of radiotherapy in the 1960s. The addition of adjuvant mechlorethamine, vincristine, procarbazine, and prednisone (MOPP)-like chemotherapies improved progression-free survival rates.

Oct 28, 2024 | onclive.com | Alex Herrera |Álex Herrera

CommentaryVideoOctober 28, 2024Author(s):Alex Herrera, MD, discusses safety and efficacy outcomes with nivolumab plus AVD vs brentuximab vedotin plus AVD in advanced classic Hodgkin lymphoma.

Apr 25, 2024 | ascopost.com | Syed Abutalib |Alex Herrera |Álex Herrera

Alex Francisco Herrera, MDClassical Hodgkin lymphoma (HL) is a highly curable disease, but up to 25% of patients will develop relapsed or refractory classical HL. Although most patients achieve complete response following front-line therapy, key unmet clinical needs include reducing the relapse rate, decreasing acute and long-term treatment-related morbidity, enhancing quality of life, and improving poor outcomes in patients older than age 60.

Mar 18, 2024 | onclive.com | Alex Herrera |Álex Herrera |Matthew A Lunning

March 18, 2024Dr Lunning sits down with Alex Herrera, MD, to discuss the frontline management of Hodgkin lymphoma, including the SWOG 1826 trial. The Blood Club, hosted by Matthew Lunning, DO, FACP, is a podcast that seeks to translate the latest hematologic oncology research findings into practical clinical implications for the treatment of patients with hematologic malignancies.